Meropenem and Pralurbactam — Competitive Intelligence Brief

Meropenem and Pralurbactam (Meropenem and Pralurbactam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (meropenem); serine beta-lactamases (pralurbactam) Infectious Disease Small molecule

Target snapshot

Meropenem and Pralurbactam (Meropenem and Pralurbactam) — Qilu Pharmaceutical Co., Ltd.. Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Meropenem and Pralurbactam TARGET	Meropenem and Pralurbactam	Qilu Pharmaceutical Co., Ltd.	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (meropenem); serine beta-lactamases (pralurbactam)
Piperacillin-tazobactam combination product	Piperacillin-tazobactam combination product	Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
cefoperazone sodium and sulbactam sodium	cefoperazone sodium and sulbactam sodium	Yung Shin Pharm. Ind. Co., Ltd.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; beta-lactamases
Imipenem+Relebactam	Imipenem+Relebactam	Wake Forest University Health Sciences	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam)
Piperacillin-tazobactam	Piperacillin-tazobactam	University Hospital, Bordeaux	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamases
high dose amoxicillin/clavulanate	high dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase
Amoxycillin/clavulanic acid	Amoxycillin/clavulanic acid	TASK Applied Science	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class